Skip to search formSkip to main contentSkip to account menu

SPA-S 565

Known as: SPA-S-565 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

rifametane

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Phase I Pharmacokinetic Study of a New 3-Azinomethyl-Rifamycin (Rifametane) as Compared to Rifampicin
An open randomized cross-over study was conducted in 8 healthy male volunteers to study the pharmacokinetic pattern and the… 
Review
1998
Review
1998
[Chemotherapeutic agents under study].
The development of new drugs with strong antituberculous activity and fewer side effects which are not cross-resistant to… 
1998
1998
Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin.
The pharmacokinetics and tolerance of a single oral dose (150 mg) of a new 3-azinomethyl rifamycin (SPA-S-565, USAN rifametane… 
Review
1994
Review
1994
[New drugs against tuberculosis and nontuberculous mycobacterial infections: a review].
The number of cases with tuberculosis is again increasing in many countries, and recently several nosocomial outbreaks of… 
1988
1988
The antibacterial activity of a new 3-azinomethyl-rifamycin.
The new 3-azinomethyl-rifamycin, SPA-S-565, was shown to exert an effective antibacterial activity in vitro comparable to that of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)